Emerging antimicrobial therapies for MDR bacterial infections

 

Emerging antimicrobial therapies for MDR bacterial infections

29 July  14.00 CEST / 20..00 AWST / 21.00 JST

Multidrug‑resistant bacterial infections continue to pose a serious global health threat, driving treatment failures, limiting therapeutic options, and increasing clinical burden across both hospital and community settings. As resistance rises, the need for innovative antimicrobial strategies has never been more urgent.

This webinar brings together leading experts from Japan and Australia to explore recent advances in antimicrobial therapy from clinical, translational, and discovery perspectives. The session will offer an integrated view of how newly approved antibiotics, bacteriophage therapy, and emerging antibacterial agents may shape the future management of multidrug‑resistant infections.

Objectives
This webinar will:

Provide an update on recently approved antibiotics for Gram‑positive and Gram‑negative bacterial infections.

Examine the clinical and translational potential of phage therapy, with particular focus on paediatric and respiratory infections.

Highlight novel therapeutic approaches for Gram‑positive pathogens, including Lysocin E as a promising emerging antibiotic candidate.

Facilitate discussion among clinicians, microbiologists, pharmacologists, infectious disease researchers, and antimicrobial resistance specialists on future directions in antimicrobial therapy.

Programme

1. Clinical aspects of recently approved antibiotics for Gram-positive and Gram-negative infections
   Speaker: Prof. Dr Shuichi Abe
2. Phage therapy for paediatric and respiratory infections
   Speaker: Assoc. Prof. Anthony Kicic
3. Novel treatments for Gram positive infections: Lysocin E as a new antibiotic
   Speaker: Prof. Hiroshi Hamamoto

 

Speakers

Professor Shuichi Abe is a clinician‑scientist in Infectious Diseases and Director and Co‑Principal Investigator at Yamagata Prefectural Central Hospital, Japan. He also works with the Pathogen Hunter’s Research Team, a Japan–Thailand collaboration focused on accelerating infectious disease discovery and response.

He specialises in respiratory infections, multidrug‑resistant bacterial infections, hospital epidemiology, antimicrobial stewardship, and infection prevention and control, with extensive experience managing complex cases across community and tertiary‑care settings.

Professor Abe’s research spans clinical infectious diseases, epidemiological surveillance, and antimicrobial resistance, with a strong focus on translating clinical evidence into improved patient care and developing strategies to address severe infections caused by multidrug‑resistant pathogens.

Today
make this into a nice descrption: Multidrug resistant bacterial infections remain a major global public health challenge, with increasing treatment failure, limited therapeutic options, and growing clinical burden across both hospital and community settings. The development and implementation of emerging antimicrobial therapies are therefore urgently needed, including recently approved antibiotics, bacteriophage therapy, and novel agents targeting difficult Gram positive and Gram-negative pathogens. This webinar will bring together international experts from Japan and Australia to discuss recent advances in antimicrobial therapy from clinical, translational, and discovery perspectives. The session will provide an integrated view of how new antibiotics, phage therapy, and novel antibacterial agents may contribute to the future management of multidrug resistant infections.
Objectives
The webinar aims to:
1. Provide an update on recently approved antibiotics for Gram positive and Gram-negative bacterial infections.
2. Discuss the clinical and translational potential of phage therapy, particularly in pediatric and respiratory infections.
3. Highlight novel therapeutic approaches for Gram positive infections, with a focus on Lysocin E as an emerging antibiotic candidate.
4. Facilitate discussion among clinicians, microbiologists, pharmacologists, infectious disease researchers, and antimicrobial resistance experts on future directions in antimicrobial therapy.
Here’s a polished, cohesive description that reads like a professional webinar overview—clear, engaging, and ready for publication:

Multidrug‑resistant bacterial infections continue to pose a serious global health threat, driving treatment failures, limiting therapeutic options, and increasing clinical burden across both hospital and community settings. As resistance rises, the need for innovative antimicrobial strategies has never been more urgent.

This webinar brings together leading experts from Japan and Australia to explore recent advances in antimicrobial therapy from clinical, translational, and discovery perspectives. The session will offer an integrated view of how newly approved antibiotics, bacteriophage therapy, and emerging antibacterial agents may shape the future management of multidrug‑resistant infections.

Objectives
This webinar will:

Provide an update on recently approved antibiotics for Gram‑positive and Gram‑negative bacterial infections.

Examine the clinical and translational potential of phage therapy, with particular focus on paediatric and respiratory infections.

Highlight novel therapeutic approaches for Gram‑positive pathogens, including Lysocin E as a promising emerging antibiotic candidate.

Facilitate discussion among clinicians, microbiologists, pharmacologists, infectious disease researchers, and antimicrobial resistance specialists on future directions in antimicrobial therapy.

If you want this in a shorter blurb, a more promotional tone, or formatted for LinkedIn/X, I can reshape it instantly.

this ok: Professor Shuichi Abe is a clinician-scientist in Infectious Diseases and serves as Director and Co-Principal Investigator in the Department of Infectious Diseases at Yamagata Prefectural Central Hospital, Japan. He is also affiliated with the Pathogen Hunter’s Research Team operates across Japan and Thailand, united by one goal: to outpace disease. Professor Abe specializes in the diagnosis, treatment, and clinical management of infectious diseases, with particular expertise in respiratory infections, multidrug-resistant bacterial infections, hospital epidemiology, antimicrobial stewardship, and infection prevention and control. His extensive clinical experience encompasses the management of complex infections in both community and tertiary-care settings.
His research focuses on clinical infectious diseases, epidemiological surveillance, antimicrobial resistance, and the translation of clinical evidence into improved patient care. Through collaborative clinical and translational research, Professor Abe contributes to the development of evidence-based strategies for the prevention and treatment of severe infectious diseases, particularly those caused by multidrug-resistant pathogens.
It’s more than ok — it’s strong, clear, and professional. If you want it to read a little smoother and more polished for a speaker bio, here’s a refined version that keeps all your content but tightens the flow and elevates the tone:

Professor Shuichi Abe is a clinician‑scientist in Infectious Diseases and serves as Director and Co‑Principal Investigator in the Department of Infectious Diseases at Yamagata Prefectural Central Hospital, Japan. He is also affiliated with the Pathogen Hunter’s Research Team, a collaborative network operating across Japan and Thailand with a shared mission to outpace emerging and established infectious threats.

Professor Abe specialises in the diagnosis, treatment, and clinical management of infectious diseases, with particular expertise in respiratory infections, multidrug‑resistant bacterial infections, hospital epidemiology, antimicrobial stewardship, and infection prevention and control. His extensive clinical practice spans both community and tertiary‑care settings, where he manages complex and severe infections.

His research focuses on clinical infectious diseases, epidemiological surveillance, antimicrobial resistance, and the translation of clinical evidence into improved patient care. Through collaborative clinical and translational research, Professor Abe contributes to the development of evidence‑based strategies for preventing and treating severe infectious diseases, especially those caused by multidrug‑resistant pathogens.

If you want it shorter, more promotional, or tailored for a webinar landing page or social media, I can reshape it.

shorter
Here’s a tighter, polished version that keeps the key details but reads smoothly:

Professor Shuichi Abe is a clinician‑scientist in Infectious Diseases and Director and Co‑Principal Investigator at Yamagata Prefectural Central Hospital, Japan. He also works with the Pathogen Hunter’s Research Team, a Japan–Thailand collaboration focused on accelerating infectious disease discovery and response.

He specialises in respiratory infections, multidrug‑resistant bacterial infections, hospital epidemiology, antimicrobial stewardship, and infection prevention and control, with extensive experience managing complex cases across community and tertiary‑care settings.

Professor Abe’s research spans clinical infectious diseases, epidemiological surveillance, and antimicrobial resistance, with a strong focus on translating clinical evidence into improved patient care and developing strategies to address severe infections caused by multidrug‑resistant pathogens.

If you want it even more concise or more promotional for a webinar page, I can trim it further.

Associate Professor Anthony Kicic is Head of Airway Epithelial Research and a Stan Perron Charitable Foundation Research Fellow. He is also a recipient of the Western Australian Cystic Fibrosis Research Collaborative Program Fellowship. His research focuses on airway epithelial biology, chronic respiratory diseases, cystic fibrosis (CF), and innovative therapies for respiratory infections.
Associate Professor Kicic leads the Western Australian arm of the Phage Australia Project, a national clinical research initiative investigating bacteriophage therapy as a precision treatment for multidrug-resistant bacterial infections. His work is particularly relevant to chronic respiratory diseases, where pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus frequently develop resistance to conventional antibiotics and contribute to progressive lung damage in patients with cystic fibrosis and other chronic lung
diseases.
His research team has identified and characterized more than 2,500 bacteriophages with activity against clinically important bacterial strains associated with severe respiratory infections. Through translational research integrating microbiology, airway biology, and precision medicine, his group aims to advance phage therapy toward routine clinical application for patients with difficult-to-treat infections.
Here’s a shorter, polished version that keeps the strongest details and reads smoothly as a speaker bio:

Associate Professor Anthony Kicic is Head of Airway Epithelial Research and a Stan Perron Charitable Foundation Research Fellow, and also holds a Western Australian Cystic Fibrosis Research Collaborative Program Fellowship. His work centres on airway epithelial biology, chronic respiratory diseases, cystic fibrosis, and innovative therapies for respiratory infections.

He leads the Western Australian arm of the Phage Australia Project, a national initiative advancing bacteriophage therapy as a precision treatment for multidrug‑resistant bacterial infections—particularly those affecting patients with chronic respiratory diseases such as cystic fibrosis.

Associate Professor Kicic’s team has identified and characterised more than 2,500 bacteriophages active against clinically important respiratory pathogens. Through translational research integrating microbiology, airway biology, and precision medicine, his group aims to move phage therapy toward routine clinical use for difficult‑to‑treat infections.

Professor Hiroshi Hamamoto is Professor of Infectious Diseases at the Department of Infectious Diseases, Faculty of Medicine, Yamagata University, Japan. His research focuses on the discovery and development of novel antimicrobial agents effective against multidrug-resistant bacterial pathogens and on elucidating the molecular mechanisms underlying bacterial and fungal pathogenicity.
Professor Hamamoto’s research integrates multidisciplinary approaches, including genomics, natural products chemistry, analytical chemistry, pharmacokinetics, toxicology, and chemical biology. These complementary methodologies support the identification of new therapeutic targets, the development of next-generation antimicrobial compounds, and the translation of fundamental discoveries into clinically relevant applications.

A/Prof. Leshan Wannigama, MD, PhD, is an Assistant Professor and Infectious Diseases Physician at Yamagata University and Yamagata University Hospital. He also leads the Pathogen Hunters Collaborative as Principal Investigator, with research focused on infectious disease diagnostics, surveillance, and novel therapeutic approaches.

Dr Jinxin Zhao is a Humboldt Research Fellow at the University of Hamburg and Bioinformatics and Computational Biology Team Lead at Monash University. He specialises in AI, bioinformatics, microbial genomics, single-cell sequencing, and mathematical modelling, developing computational approaches to understand antimicrobial resistance, bacterial evolution, and host–pathogen interactions. His work bridges data science and microbiology to support next-generation infectious disease research.